Immune system and melanoma biology: a balance between immunosurveillance and immune escape

Anna Passarelli _, Francesco Mannavola, Luigia Stefania Stucci, Marco Tucci and Francesco Silvestris

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:106132-106142. https://doi.org/10.18632/oncotarget.22190

Metrics: PDF 1761 views  |   HTML 2623 views  |   ?  


Anna Passarelli1, Francesco Mannavola1, Luigia Stefania Stucci1, Marco Tucci1 and Francesco Silvestris1

1Department of Biomedical Sciences and Human Oncology, University of Bari ‘Aldo Moro’, Bari, Italy

Correspondence to:

Anna Passarelli, email: passarellian@libero.it

Keywords: melanoma; immune system; immunogenicity; immunoediting; immune escape

Received: May 26, 2017    Accepted: September 21, 2017    Published: October 31, 2017


Melanoma is one of the most immunogenic tumors and its relationship with host immune system is currently under investigation. Many immunomodulatory mechanisms, favoring melanomagenesis and progression, have been described to interfere with the disablement of melanoma recognition and attack by immune cells resulting in immune resistance and immunosuppression. This knowledge produced therapeutic advantages, such as immunotherapy, aiming to overcome the immune evasion.

Here, we review the current advances in cancer immunoediting and focus on melanoma immunology, which involves a dynamic interplay between melanoma and immune system, as well as on effects of “targeted therapies” on tumor microenvironment for combination strategies.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22190